Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY ...

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

Mainz Biomed (MYNZ) announced an agreement with Quest Diagnostics (DGX), a leading provider of diagnostic information services, to support ...

Originally published in Quest Diagnostics' 2023 Corporate Responsibility Report Minimizing our environmental impact ...

led largely by Laboratory Corporation of America and Quest Diagnostics snatching up outreach laboratory assets from regional health systems or testing assets from larger firms like Invitae and Opko ...

Clinical reference laboratory market size was valued at USD 45.6 billion in 2023 and is projected to grow at a 6.2% CAGR from 2024 to 2032. Clinical reference laboratories, specialized in performing ...

Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool ...

In a world grappling with a multitude of health threats—ranging from fast-spreading viruses to chronic diseases and ...

Researchers have developed microchips using field-effect transistors that can detect multiple diseases from a single air sample with high sensitivity. The technology enables rapid testing and could ...